DA Davidson analyst Peter Heckmann maintains AppFolio (NASDAQ:APPF) with a Neutral and raises the price target from $95 to $100.
Lilly’s Strategic Branding Move For Weight Loss Drug Sets Stage For Long Term Success – Analyst
Wednesday, the FDA approved Eli Lilly And Co's (NYSE: LLY) Zepbound (tirzepatide) injection, the first and